文献检索文档翻译深度研究
Suppr Zotero 插件Zotero 插件
邀请有礼套餐&价格历史记录

新学期，新优惠

限时优惠:9月1日-9月22日

30天高级会员仅需29元

1天体验卡首发特惠仅需5.99元

了解详情
不再提醒
插件&应用
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
高级版
套餐订阅购买积分包
AI 工具
文献检索文档翻译深度研究
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2025

癌症中的 CD4 T 细胞。

CD4 T cells in cancer.

机构信息

Department of Oncology, Lausanne University Hospital Center (CHUV) and University of Lausanne, Lausanne, Switzerland.

Department of Cellular Immunotherapy, Institute of Experimental Immunology, University of Zürich, Zürich, Switzerland.

出版信息

Nat Cancer. 2023 Mar;4(3):317-329. doi: 10.1038/s43018-023-00521-2. Epub 2023 Mar 9.

DOI:10.1038/s43018-023-00521-2
PMID:36894637
Abstract

Cancer immunology and immunotherapy are driving forces of research and development in oncology, mostly focusing on CD8 T cells and the tumor microenvironment. Recent progress highlights the importance of CD4 T cells, corresponding to the long-known fact that CD4 T cells are central players and coordinators of innate and antigen-specific immune responses. Moreover, they have now been recognized as anti-tumor effector cells in their own right. Here we review the current status of CD4 T cells in cancer, which hold great promise for improving knowledge and therapies in cancer.

摘要

癌症免疫学和免疫疗法是肿瘤学研究和开发的主要驱动力，主要集中在 CD8 T 细胞和肿瘤微环境上。最近的进展强调了 CD4 T 细胞的重要性，这与 CD4 T 细胞是先天和抗原特异性免疫反应的核心参与者和协调者这一长期公认的事实相对应。此外，它们现在已经被认为是具有抗肿瘤效应的细胞。在这里，我们回顾了 CD4 T 细胞在癌症中的现状，这为提高癌症的知识和治疗水平提供了巨大的希望。

相似文献

[1]
CD4 T cells in cancer.

Nat Cancer. 2023-3

[2]
Toward T Cell-Mediated Control or Elimination of HIV Reservoirs: Lessons From Cancer Immunology.

Front Immunol. 2019-9-10

[3]
CD4 T-cell epitope-based heterologous prime-boost vaccination potentiates anti-tumor immunity and PD-1/PD-L1 immunotherapy.

J Immunother Cancer. 2022-5

[4]
Stromal PD-L1-Positive Regulatory T cells and PD-1-Positive CD8-Positive T cells Define the Response of Different Subsets of Non-Small Cell Lung Cancer to PD-1/PD-L1 Blockade Immunotherapy.

J Thorac Oncol. 2017-12-18

[5]
Regulation and impact of tumor-specific CD4 T cells in cancer and immunotherapy.

Trends Immunol. 2024-4

[6]
Checkpoint blockade immunotherapy enhances the frequency and effector function of murine tumor-infiltrating T cells but does not alter TCRβ diversity.

Cancer Immunol Immunother. 2019-5-18

[7]
CD4+ T cells induce rejection of urothelial tumors after immune checkpoint blockade.

JCI Insight. 2018-12-6

[8]
MHC class I TCR engineered anti-tumor CD4 T cells: implications for cancer immunotherapy.

Endocr Metab Immune Disord Drug Targets. 2009-12

[9]
The role of CD4 T cells in rejection of solid tumors.

Curr Opin Immunol. 2022-2

[10]
Molecular heterogeneity of anti-PD-1/PD-L1 immunotherapy efficacy is correlated with tumor immune microenvironment in East Asian patients with non-small cell lung cancer.

Cancer Biol Med. 2020-8-15

引用本文的文献

[1]
From trash to treasure: tumor draining lymph nodes as a multi-omics goldmine in cancer therapy.

Front Oncol. 2025-8-19

[2]
The Predictive Significance of Interleukin-2 Receptor in Patients with Hepatocellular Carcinoma.

J Hepatocell Carcinoma. 2025-8-22

[3]
Immunological Landscape and Molecular Therapeutic Targets of the Tumor Microenvironment in Hepatocellular Carcinoma.

Int J Mol Sci. 2025-8-13

[4]
UBE2N as a novel prognostic and therapeutic biomarker of lung adenocarcinoma.

Front Immunol. 2025-8-11

[5]
Nanoengineered-based delivery systems to modulate CD4 T cell responses in cancer: emerging paradigms in cancer immunotherapy.

Front Pharmacol. 2025-8-11

[6]
The Role of Senescence, its Therapeutic Relevance and Clinical Implications in the Tumor Microenvironment.

Theranostics. 2025-7-28

[7]
Immune Profiling among Colorectal Cancer Subtypes using Dependent Mixture Models.

J Am Stat Assoc. 2025

[8]
FEN1 plays a key role in the transition from HSIL to CSCC.

Sci Rep. 2025-8-17

[9]
Silver Jubilee of HER2 targeting: a clinical success in breast cancer.

J Natl Cancer Cent. 2025-2-12

[10]
Immunological synapse: structures, molecular mechanisms and therapeutic implications in disease.

Signal Transduct Target Ther. 2025-8-11

本文引用的文献

[1]
Lymph node colonization induces tumor-immune tolerance to promote distant metastasis.

Cell. 2022-5-26

[2]
Landscape of helper and regulatory antitumour CD4 T cells in melanoma.

Nature. 2022-5

[3]
The interaction of CD4 helper T cells with dendritic cells shapes the tumor microenvironment and immune checkpoint blockade response.

Nat Cancer. 2022-3

[4]
A decade of checkpoint blockade immunotherapy in melanoma: understanding the molecular basis for immune sensitivity and resistance.

Nat Immunol. 2022-5

[5]
RNF2 ablation reprograms the tumor-immune microenvironment and stimulates durable NK and CD4 T-cell-dependent antitumor immunity.

Nat Cancer. 2021-10

[6]
Tumor-associated high endothelial venules mediate lymphocyte entry into tumors and predict response to PD-1 plus CTLA-4 combination immunotherapy.

Cancer Cell. 2022-3-14

[7]
Lung tumor MHCII immunity depends on in situ antigen presentation by fibroblasts.

J Exp Med. 2022-2-7

[8]
Cytotoxic CD4 T cells in cancer: Expanding the immune effector toolbox.

Immunity. 2021-12-14

[9]
Dynamic CD4 T cell heterogeneity defines subset-specific suppression and PD-L1-blockade-driven functional restoration in chronic infection.

Nat Immunol. 2021-12

[10]
Macrophage-Targeted Therapy Unlocks Antitumoral Cross-talk between IFNγ-Secreting Lymphocytes and IL12-Producing Dendritic Cells.

Cancer Immunol Res. 2022-1

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

推荐工具

医学文档翻译智能文献检索